CN104768577B - 高压设备和用于制备灭活疫苗和用于重折叠/增溶重组蛋白的方法 - Google Patents

高压设备和用于制备灭活疫苗和用于重折叠/增溶重组蛋白的方法 Download PDF

Info

Publication number
CN104768577B
CN104768577B CN201380054922.4A CN201380054922A CN104768577B CN 104768577 B CN104768577 B CN 104768577B CN 201380054922 A CN201380054922 A CN 201380054922A CN 104768577 B CN104768577 B CN 104768577B
Authority
CN
China
Prior art keywords
pressure
bar
high pressure
inactivated
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380054922.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN104768577A (zh
Inventor
N·P·Y·卡波莱克
G·枚里安
R·拉巴图特
L·格伦特斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TOP INDUSTRIE Sas
Merial Ltd
Original Assignee
TOP INDUSTRIE Sas
Merial Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TOP INDUSTRIE Sas, Merial Ltd filed Critical TOP INDUSTRIE Sas
Publication of CN104768577A publication Critical patent/CN104768577A/zh
Application granted granted Critical
Publication of CN104768577B publication Critical patent/CN104768577B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
    • A23B2/00—Preservation of foods or foodstuffs, in general
    • A23B2/10—Preservation of foods or foodstuffs, in general by treatment with pressure variation, shock, acceleration or shear stress
    • A23B2/103—Preservation of foods or foodstuffs, in general by treatment with pressure variation, shock, acceleration or shear stress using sub- or super-atmospheric pressures, or pressure variations transmitted by a liquid or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/02—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using physical processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/01—Methyltransferases (2.1.1)
    • C12Y201/01041—Sterol 24-C-methyltransferasee (2.1.1.41)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0031—Serum-free culture media
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
    • C12N9/60—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from yeast
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Sustainable Development (AREA)
CN201380054922.4A 2012-08-30 2013-08-30 高压设备和用于制备灭活疫苗和用于重折叠/增溶重组蛋白的方法 Active CN104768577B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261694968P 2012-08-30 2012-08-30
US61/694,968 2012-08-30
US201361830425P 2013-06-03 2013-06-03
US61/830,425 2013-06-03
PCT/US2013/057426 WO2014036345A2 (en) 2012-08-30 2013-08-30 Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing recombinant proteins

Publications (2)

Publication Number Publication Date
CN104768577A CN104768577A (zh) 2015-07-08
CN104768577B true CN104768577B (zh) 2020-06-09

Family

ID=49162270

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201380054922.4A Active CN104768577B (zh) 2012-08-30 2013-08-30 高压设备和用于制备灭活疫苗和用于重折叠/增溶重组蛋白的方法
CN201810318137.XA Pending CN108578679A (zh) 2012-08-30 2013-08-30 嵌合ksac蛋白的表达和由高压产生可溶性蛋白的方法
CN201380053720.8A Pending CN104717976A (zh) 2012-08-30 2013-08-30 嵌合ksac蛋白的表达和由高压产生可溶性蛋白的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201810318137.XA Pending CN108578679A (zh) 2012-08-30 2013-08-30 嵌合ksac蛋白的表达和由高压产生可溶性蛋白的方法
CN201380053720.8A Pending CN104717976A (zh) 2012-08-30 2013-08-30 嵌合ksac蛋白的表达和由高压产生可溶性蛋白的方法

Country Status (18)

Country Link
US (3) US9315553B2 (enExample)
EP (2) EP2890393A2 (enExample)
JP (2) JP6405308B2 (enExample)
KR (1) KR102208844B1 (enExample)
CN (3) CN104768577B (enExample)
AP (1) AP2015008331A0 (enExample)
AU (4) AU2013308627B2 (enExample)
BR (1) BR112015004463B8 (enExample)
CA (2) CA2883296A1 (enExample)
EA (1) EA031988B1 (enExample)
ES (1) ES2744709T3 (enExample)
HK (1) HK1211874A1 (enExample)
MD (1) MD4608C1 (enExample)
MX (3) MX381717B (enExample)
NZ (3) NZ705790A (enExample)
PH (1) PH12015500700B1 (enExample)
RU (1) RU2647568C2 (enExample)
WO (2) WO2014036345A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8968749B2 (en) * 2006-07-21 2015-03-03 Universidade Federal De Minas Gerais—Ufmg Vaccine composition and immunization method
ZA201501696B (en) 2012-08-30 2016-01-27 Merial Ltd Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing recombinant proteins
KR102208844B1 (ko) * 2012-08-30 2021-01-27 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 고압 디바이스 및 불활성화된 백신을 생산하고 재조합 단백질을 리폴딩/가용화하는 방법
WO2014160987A2 (en) * 2013-03-28 2014-10-02 Infectious Disease Research Institute Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
CN104758944B (zh) * 2015-04-02 2017-11-28 中国科学院过程工程研究所 一种疫苗制剂及其制备方法和用途
JP2018082987A (ja) * 2016-11-25 2018-05-31 株式会社日立製作所 ウイルス不活化方法及びウイルス不活化装置
JP2020152644A (ja) * 2019-03-18 2020-09-24 国立大学法人愛媛大学 Ｖｎａｒのリフォールディング方法およびｖｎａｒの製造方法
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
CN112120012B (zh) * 2020-09-30 2022-03-22 广东康盾创新产业集团股份公司 一种car-t细胞冻存方法
BR102021000794A2 (pt) * 2021-01-15 2022-07-26 Fundação Oswaldo Cruz Proteína quimérica, kit, método para diagnóstico de leishmaniose, uso de uma proteína quimérica, composição vacinal contra leishmaniose visceral, e, uso de uma composição vacinal

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN200945252Y (zh) * 2006-09-01 2007-09-12 天津市华泰森淼生物工程技术有限公司 手动开启式小型超高压生物处理设备
CN201781934U (zh) * 2010-04-14 2011-04-06 中国农业大学 一种小型框架自动式超高压设备

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
JP2743177B2 (ja) * 1987-04-24 1998-04-22 財団法人阪大微生物病研究会 百日咳菌の培養方法、及び百日咳トキソイドとその混合ワクチン
JP4111403B2 (ja) 1996-10-11 2008-07-02 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 免疫刺激ポリヌクレオチド／免疫調節分子複合体
US5980912A (en) 1997-03-25 1999-11-09 Zonagen, Inc. Chitosan induced immunopotentiation
FR2771011B1 (fr) 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
FR2776928B1 (fr) 1998-04-03 2000-06-23 Merial Sas Vaccins adn adjuves
US6489450B2 (en) 1998-07-09 2002-12-03 University Technology Corporation High pressure refolding of protein aggregates and inclusion bodies
WO2000072703A1 (en) 1999-05-28 2000-12-07 UNIVERSITé LAVAL Inactivation of food spoilage and pathogenic microorganisms by dynamic high pressure
US6645740B1 (en) 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
IL148843A0 (en) 1999-09-25 2002-09-12 Univ Iowa Res Found Immunostimulatory nucleic acids
US7615617B2 (en) 1999-10-25 2009-11-10 University Of Delaware Use of hydrostatic pressure to inhibit and reverse protein aggregation and facilitate protein refolding
WO2002056824A2 (en) 2000-08-10 2002-07-25 Boston Biomedica, Inc. Pressure cycling inactivation of pathogens in biological materials used for therapeutics or vaccines
US6635223B2 (en) 2000-10-25 2003-10-21 Andreas Maerz Method for inactivating micro-organisms using high pressure processing
WO2002062827A2 (en) * 2000-10-31 2002-08-15 The Regents Of The University Of Colorado, A Body Corporate Improved protein disaggregation and refolding using high pressure
AU2003245416A1 (en) 2002-06-07 2004-04-30 University Of Florida Endodontic files made using bulk metallic glasses
SE525457C2 (sv) * 2002-06-24 2005-02-22 Flow Holdings Sagl Förfarande för åstadkommande av en tryckändring mellan två trycktillstånd, högtryckspressanordning samt användning av förfarande eller högtryckspressanordning
RS52507B (sr) * 2003-11-05 2013-04-30 Laboratorios Leti S.L. Primena specifičnih histona za lečenje parazitnih bolesti
US7993580B2 (en) 2004-08-24 2011-08-09 Baxter International Inc. Methods for the inactivation of microorganisms in biological fluids, flow through reactors and methods of controlling the light sum dose to effectively inactivate microorganisms in batch reactors
JP2009519706A (ja) 2005-11-21 2009-05-21 バロフォールド， インコーポレイテッド タンパク質の高圧リフォールディングのためのデバイスおよび方法
EP2059523A2 (en) 2006-09-15 2009-05-20 Barofold, Inc. High pressure treatment of proteins for reduced immunogenicity
WO2008124134A2 (en) 2007-04-05 2008-10-16 Barofold, Inc. High-pressure refolding of proteins in the presence of binding partners
WO2008124139A1 (en) 2007-04-05 2008-10-16 Barofold, Inc. High pressure inclusion body solubilization in the presence of a protease
US8273561B2 (en) 2007-10-05 2012-09-25 Nuron Biotech, Inc. High pressure treatment of aggregated interferons
RU2440137C1 (ru) * 2007-12-21 2012-01-20 Пфайзер Инк. Термообработанные бактерины и эмульсионные вакцины, полученные из таких термообработанных бактеринов
BRPI0800357A2 (pt) 2008-03-10 2009-10-27 Fundacao Oswaldo Cruz método para produção de uma vacina estabilizada
US8603808B2 (en) 2008-05-08 2013-12-10 Merial Limited Leishmania vaccine using sand fly salivary immunogen
US8410258B2 (en) * 2008-05-21 2013-04-02 Infections Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
US8425919B2 (en) 2008-05-21 2013-04-23 Infectious Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
WO2009155102A2 (en) 2008-05-30 2009-12-23 Barofold, Inc. Method for derivatization of proteins using hydrostatic pressure
US20110070219A1 (en) 2009-04-27 2011-03-24 Seefeldt Matthew B High pressure protein crystallization
EP2531042A1 (en) * 2010-02-01 2012-12-12 Avure Technologies AB High-pressure arrangement with locking element preventing rotation of load basket
US8697848B2 (en) 2010-07-19 2014-04-15 The Regents Of The University Of Colorado Method for reducing immunogenicity of therapeutic protein compositions
KR102208844B1 (ko) 2012-08-30 2021-01-27 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 고압 디바이스 및 불활성화된 백신을 생산하고 재조합 단백질을 리폴딩/가용화하는 방법
ZA201501696B (en) * 2012-08-30 2016-01-27 Merial Ltd Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing recombinant proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN200945252Y (zh) * 2006-09-01 2007-09-12 天津市华泰森淼生物工程技术有限公司 手动开启式小型超高压生物处理设备
CN201781934U (zh) * 2010-04-14 2011-04-06 中国农业大学 一种小型框架自动式超高压设备

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Confronting high-throughput protein refolding using high pressure and solution screens;M. Walid Qoronfleh等;《Protein Expression and Purification》;20070602;第55卷(第2期);摘要，表3，第220页左栏第二段 *
M. Walid Qoronfleh等.Confronting high-throughput protein refolding using high pressure and solution screens.《Protein Expression and Purification》.2007,第55卷(第2期), *

Also Published As

Publication number Publication date
EP2890392A1 (en) 2015-07-08
NZ715459A (en) 2017-05-26
AU2017201724A1 (en) 2017-03-30
NZ706288A (en) 2016-06-24
CN104717976A (zh) 2015-06-17
MX381717B (es) 2025-03-13
PH12015500700B1 (en) 2018-11-28
AU2017201724B2 (en) 2019-01-17
WO2014036345A2 (en) 2014-03-06
PH12015500700A1 (en) 2015-05-25
JP2015529462A (ja) 2015-10-08
US9169302B2 (en) 2015-10-27
US9315553B2 (en) 2016-04-19
WO2014036345A3 (en) 2014-06-26
ES2744709T3 (es) 2020-02-26
EA031988B1 (ru) 2019-03-29
JP6405308B2 (ja) 2018-10-17
BR112015004463B1 (pt) 2021-08-24
MX358782B (es) 2018-09-04
AP2015008331A0 (en) 2015-03-31
RU2647568C2 (ru) 2018-03-16
EP2890393A2 (en) 2015-07-08
KR20150063403A (ko) 2015-06-09
US10364274B2 (en) 2019-07-30
WO2014036349A1 (en) 2014-03-06
MD4608C1 (ro) 2019-07-31
CA2883296A1 (en) 2014-03-06
RU2015111255A (ru) 2016-10-20
BR112015004463A2 (pt) 2017-08-08
AU2013308623A1 (en) 2015-04-02
NZ705790A (en) 2016-06-24
HK1211874A1 (zh) 2016-06-03
BR112015004463B8 (pt) 2022-06-28
JP6438396B2 (ja) 2018-12-12
EA201500275A1 (ru) 2015-07-30
US20140072594A1 (en) 2014-03-13
CN104768577A (zh) 2015-07-08
JP2015528466A (ja) 2015-09-28
EP2890392B1 (en) 2019-04-17
AU2013308623B2 (en) 2017-03-02
CA2883303A1 (en) 2014-03-06
HK1211873A1 (en) 2016-06-03
MX2021004478A (es) 2021-06-04
AU2013308627A1 (en) 2015-04-09
MD4608B1 (ro) 2018-12-31
MX2015002701A (es) 2015-12-01
MD20150031A2 (ro) 2015-10-31
MX2015002699A (es) 2015-12-01
AU2017200301A1 (en) 2017-02-16
KR102208844B1 (ko) 2021-01-27
CN108578679A (zh) 2018-09-28
US20170081372A1 (en) 2017-03-23
AU2013308627B2 (en) 2016-10-27
US20140065187A1 (en) 2014-03-06

Similar Documents

Publication Publication Date Title
AU2017201724B2 (en) Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing
Shams Recent developments in veterinary vaccinology
Faisal et al. Leptospira immunoglobulin-like protein A variable region (LigAvar) incorporated in liposomes and PLGA microspheres produces a robust immune response correlating to protective immunity
JP2009523158A (ja) 熱可逆性水中油滴型エマルション
EA036764B1 (ru) Ослабленный штамм streptococcus suis, индуцирующий иммунный ответ у свиней, и его применение
TR201815419T4 (tr) Ospa'nin mutant fragmanlari ve bunlarla i̇lgi̇li̇ yöntemler ve kullanimlar
US10080791B2 (en) Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing recombinant proteins
CN105682680A (zh) 增强对结核病的免疫
WO2005001059A2 (en) Inactivating organisms using carbon dioxide at or near its supercritical pressure and temperature conditions
Li et al. A Bacterial mRNA‐Lysis‐Mediated Cargo Release Vaccine System for Regulated Cytosolic Surveillance and Optimized Antigen Delivery
Di Emidio et al. Efficacy and safety studies on an inactivated vaccine against bluetongue virus serotype 2
CN104981252B (zh) 包含支原体抗原的免疫原性组合物
Verfaillie et al. Priming of piglets against enterotoxigenic E. coli F4 fimbriae by immunisation with FAEG DNA
Wibowo et al. Non-chromatographic preparation of a bacterially produced single-shot modular virus-like particle capsomere vaccine for avian influenza
CA3074004A1 (en) Streptococcus suis vaccines to protect against reproductive, nursery-age, and growing pig diseases and methods of making and use thereof
Oledzka et al. Toxoplasma gondii: Immunological response of sheep to injections of recombinant SAG1, SAG2, GRA1 proteins coupled to the non-toxic microparticle muramyl dipeptide
Ferreira Júnior et al. Immunization of hens
Zhang et al. Immunoadjuvant effects of hemagglutinating virus of Japan envelope (HVJ-E) on the inactivated H9 subtype avian influenza virus vaccine
Nagdive et al. Protective Efficiency of Pasteurella multocida A: 1 Bacteriophage lysate Vaccine against Homologous and Heterologous Challenge in Poultry
Salvador-Mira et al. Erythrocyte-targeted recombinant subunit vaccine: A novel approach to improve viral vaccines in fish
US11213579B2 (en) Vaccines with enhanced immunogenicity, low allergenicity and reactogenicity
Shihab et al. Recombinant listeriolysin-O as a platform for next-generation vaccines: Mechanisms, immunological evidence, and translational applications in human and veterinary medicine
De Melo Barbosa Production Technologies, Regulatory Parameters, and Quality Control of Vaccine Vectors for Veterinary Use
Nagdive et al. Serotypes protective immune response of Pasteurella multocida A: 1 phage lysate vaccine in murine model.
RU2643335C1 (ru) Инактивированная бивалентная гидроокись алюминиевая вакцина против кампилобактериоза собак

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant